1,671 reports of this reaction
1.9% of all WARFARIN SODIUM reports
#10 most reported adverse reaction
ANAEMIA is the #10 most commonly reported adverse reaction for WARFARIN SODIUM, manufactured by Upsher-Smith Laboratories, LLC. There are 1,671 FDA adverse event reports linking WARFARIN SODIUM to ANAEMIA. This represents approximately 1.9% of all 87,043 adverse event reports for this drug.
WARFARIN SODIUM has an overall safety score of 92 out of 100. Patients taking WARFARIN SODIUM who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for WARFARIN SODIUM, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for WARFARIN SODIUM:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 1,671 FDA reports for WARFARIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 1.9% of all adverse event reports for WARFARIN SODIUM, making it a notable side effect.
If you experience anaemia while taking WARFARIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.